Source: Healio Coverage
August 05, 2020
1 min read

Top in endocrinology: Diabetes, hypertension and COVID-19

Source: Healio Coverage
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

New data indicate that the prevalence of diabetes and hypertension among patients with COVID-19 is lower than previously reported. It was the top story in endocrinology last week.

Another top story is about a study that showed the risk for metabolic syndrome is higher among postmenopausal women than premenopausal women.

blood pressure monitor
Risks for ICU admission and death from COVID-19 are higher for adults with diabetes and hypertension, data show. Photo credit: Adobe Stock.

Read these and more top stories in endocrinology below:

Prevalence of diabetes, hypertension among COVID-19 patients likely lower than reported

Risks for ICU admission and death from COVID-19 are higher for adults with diabetes and hypertension, but the number of patients with COVID-19 who have diabetes and hypertension may be lower than previously reported, according to a recent study. Read more.

Risk for metabolic syndrome rises after menopause

Postmenopausal women are more likely to have metabolic syndrome compared with premenopausal women, putting them at an increased risk for heart disease and stroke, according to a study published in Menopause. Read more.

Both central, general adiposity lead to higher risks for kidney disease

Risks for kidney disease rise with increasing adiposity, regardless of fat distribution and presence of diabetes, according to a study published in the International Journal of Obesity. Read more.

Exercise immediately after insulin dosing ‘unsafe’: Pilot study

A low insulin level coupled with euglycemia or modest hyperglycemia are the most favorable conditions for exercise for people with type 1 diabetes, findings from a small pilot study suggest. Read more.

Delayed denosumab injections raise vertebral fracture risks

Delaying denosumab (Prolia, Amgen) doses by more than 4 months was associated with increased risks for vertebral fracture compared with on-time injections, according to findings published in Annals of Internal Medicine. Read more.